Leading pharmaceutical manufacturer, Aesica, has today (Friday November 18) officially opened its new £3 million Potent Manufacturing Facility in Queenborough, Kent. The new facility, which will significantly enhance and extend Aesica’s capabilities in terms of formulated products and the packaging of solid dosage forms, was opened by Cllr Ben Stokes and Cllr Sylvia Bennett, the Mayor and Mayoress of Swale, who unveiled an official commemorative plaque. Gordon Henderson, MP for Sittingbourne and Sheppey was also in attendance.
Aesica chose to build the facility at Queenborough as the site already manufactures potent APIs and therefore had extensive formulation expertise and experience in handling controlled drugs. With the addition of the new facility, Aesica now has the opportunity to manufacture potent formulated products typically classified as SafeBridge ® Category 3. In addition, the new facility’s comprehensive security measures also enable it to manufacture Schedule II controlled drugs such as opiates.
Housed in a purpose built facility, the Potent Manufacturing Facility unit includes suites for blending, compression and blistering along with the appropriate HVAC and cleaning facilities. It is completely separate from the rest of the company’s facilities to prevent any potential cross-contamination and there is also space for expansion into granulation technology. Aesica is one of only two companies in the UK with such facilities and as the evolution of drug development and the use of more potent compounds has made high containment drug manufacturing a key focus for customers outsourcing their products, Aesica is predicting the new facility will play a pivotal role in increasing its share of the contract manufacturing market.
Speaking at the opening, Simon Clough, Managing Director, Formulated Products Business Unit, Aesica said: “We have a proven record in the development and manufacture of Formulated Products and APIs and so it was a natural progression to broaden our reach into this marketplace. Aesica’s service offering and capability is the most advanced in the UK and the addition of the new facility will be of huge benefit to our current clients and indeed all pharmaceutical companies who require potent drug product production. In fact, one thing we will be looking at is the manufacture of a narcotic analgesic for severe pain relief.”
Mayor of Swale, Cllr Ben Stokes, said after unveiling the plaque to mark the opening: I am delighted to be here to officially open this superb state-of-the-art facility, which really shows the confidence Aesica has in its Queenborough plant and will ensure this area continues to be a major player in the field of pharmaceutical technology.
Gordon Henderson MP said: Aesica’s manufacturing site here at Queenborough is constantly growing and this extensive investment by the company is a real thumbs up to the excellent work being done by the talented team here.
Aesica is a leading full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements. Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within Aesica enables it to provide primary and secondary contract manufacturing services to the highest possible regulatory standards. It is this full-service offer, its dedication to exceptional standards of service and its ability to deliver innovation and added value for its clients that truly sets Aesica apart from its counterparts.